Dr. Young Hahn Awarded NIH STTR for $107,656 to Validate a Novel Therapeutic Approach for Liver Fibrosis Treatment
Vasarya Therapeutics, Inc., was awarded an NIH STTR (Small Business Technology Transfer) with Dr. Young Hahn to validate a novel therapeutic approach for liver fibrosis treatment. Liver fibrosis represents a significant financial burden on the U.S. health system, and to … Read More










